Management Team and Board of Directors
CEO and Chairman
Mr. Royea was recognized as one of the Top 40 Transformers in Health Care by MM&M Magazine in 2016, and Cyrcadia was awarded the Gold Edison Award for Top Wearable and Sensor product in Health and Wellness for 2016. He is a proven senior executive offering comprehensive knowledge in the creation, and execution, of the strategies necessary to grow sophisticated medical technology and software companies. He has led global efforts of both public and private venture backed technologies, with demonstrated successes from start-up to over $550M in P & L responsibilities.
Mr. Royea designed the go-to-market strategies, hired clinical and marketing teams, and executed on the business perspectives for the cardiac ultrasound and cardiac PACS divisions of Acuson, to achieve number one market positions world-wide. He eventually became the general manager for Siemens Medical’s ultrasound, PACS and catheter division for the US helping to pioneer the use of high frequency ultrasound as a key adjunctive tool to mammography for dense breast tissue analysis. Most recently, Mr. Royea lead the global launch, and eventual sale of Ziosoft, renamed Qi Imaging, Inc. a super computed algorithmic medical imaging company to Dr. Patrick Soon-Shiong’s Nantworks, to enable a centralized patient data intelligent domain containing imaging, genomic and proteomic data targeted at cardiovascular and cancer research.
Jim Holmes, Founder and Treasurer
Chairman of the Board - Lifeline Biotechnologies, Inc.
Mr. Holmes serves and has served on the board of directors of numerous public and private companies. He holds or has held positions of chief executive officer, chief financial officer providing management support in executive, administrative, financial and marketing functions. Currently he is president of Carson Capital Management, Inc., a management, merger/acquisition and investment banking consulting firm. His background includes corporate mergers/acquisitions, having consolidated, financed, or listed over a dozen companies.
Mr. Holmes has formerly served as assistant controller of Bio Rad Labs(AMEX); CEO of Harvest Industries(OTC); vice-president of North Coast Investments, a venture capital firm and on the audit staff of Pricewaterhouse Coopers. Mr. Holmes is a mentor and judge in the University of Notre Dame’s business plan competition program. He has been a guest speaker at San Jose State-DeAnza College’s Entrepreneurial Incubator program and guest lecturer at University of Nevada, Reno’s Business Development, and Venture Capital program. He completed graduate studies at Golden Gate University’s MBA program and holds a Bachelor’s of Science degree in Business from San Jose State University, and has also completed Stanford’s Advance Management College. Mr. Holmes is currently a Ph.D. candidate in Financial Economics at Rushmore University.
Co-Founder and Director - Vice President
Mr. Benardis is a significant investor in the company and co-founder. Mr. Benardis undertook daily operations since inception with a focus on product and market development, as well as fundraising, IP management, strategic planning, and acts as management representative for the Cyrcadia Quality Assurance program. Recently, Mr. Benardis’ role has evolved to focus on upcoming product releases in his position as Internal Regulatory Agent and has been voted to the Board of Directors.
Mr. Benardis has been with the company since its inception in 2008 serving a number of critical functions within the organization as Cyrcadia converts from research and development to market deployment.
Vinitha Sree Subbhuraam, Ph.D.
Director – Customer Analytic Core Lab
Vinitha has over ten years of experience in the medical analytics field, and has applied predictive analytics for designing clinical decision support systems for the detection of diseases like carotid atherosclerosis, fatty liver, diabetes, epilepsy, and cancers in the thyroid, breast, ovaries and prostate. Her primary focus is on developing early detection techniques for breast cancer. During her doctoral study at Nanyang Technological University (NTU), Singapore, she used data mining strategies to evaluate an adjunct breast cancer detection modality that used skin surface electropotentials for analysis. Subsequently, as a Research Associate at NTU, she studied Cyrcadia’s initial clinical trial datasets, used data mining techniques to understand the skin surface temperature pattern differences between benign and malignant breast cancer cases, and developed an effective predictive model to detect the presence of cancer. She has collaborated with leading research institutions and hospitals in the world, and has successfully liaised with scientists from North America, Europe and Asia Pacific to establish a global network to continue her efforts in breast cancer research.
Dr. Sree has published 88 journal papers, conference articles and book chapters, and her work is internationally recognized by her peers as evidenced by more than 725 citations to her work. She is the co-editor of the book Diagnostic and Therapeutic Applications of Breast Imaging published by SPIE, USA, 2012. She is the associate editor of the Journal of Medical Imaging and Health Informatics (JMIHI), and an invited reviewer for several international journals such as International Journal of Thermal Sciences, IEEE Transactions on Biomedical Engineering, Physical Review, IEEE Transactions on Information Technology in Biomedicine, Artificial Intelligence in Medicine, Computers in Biology and Medicine, Journal of Mechanics in Medicine and Biology, Neural Computing and Applications, and Neurocomputing. She holds M.S. and Ph.D. degrees in Biomedical Engineering from NTU, and a Bachelor’s degree in Electronics and Communication Engineering from PSG College of Technology, India. Dr. Sree’s biographical profile has been included twice in Marquis Who’s Who in the World (2011 and 2014 editions).
Shyamali Mallick Singhal, MD, PhD, FACS
Acting Chief Medical Officer, Board of Directors, Founding Director and Surgical Oncologist at El Camino Cancer Hospital, Mt. View CA
Dr. Singhal is originally from San Mateo and went to Baltimore to receive her undergraduate degree in Biophysics at Johns Hopkins University. She then attended the Albert Einstein College of Medicine in New York where she completed her M.D. program while also receiving a Ph.D. in Molecular Pharmacology. Dr. Singhal has extensive training in the cellular and molecular bases for cancer as well as the chemo, radiological, and surgical treatment of the disease, providing Dr. Singhal with a comprehensive view of cancer and a better opportunity to treat the disease.
When Dr. Singhal was completing her residency, she was amazed by the incredible improvement that complex surgery could have on health of cancer patients. This inspired her to focus her medical career on surgical oncology. She went on to complete a fellowship in Surgical Oncology at the City of Hope National Cancer Center, a leader in Minimally Invasive Surgical Oncology (MISO). Her research there focused on discovering the interactions of chemotherapy and a wide spectrum of natural agents, and the impact on liver function. She completed her Surgical Residency at the University of Washington in Seattle in one of the nation’s top surgical training programs. Dr. Singhal completed her M.D. and Ph.D. from the Albert Einstein College of Medicine in New York. She completed her PhD there in the department of Molecular Pharmacology with the thesis, Studies in the Regulation of the mdr1b gene by Progesterone.
Constance E. Skidmore
Board of Directors
Connie is the Chairman of the Audit Committee of Comfort Systems USA (NYSE: FIX), a $1.4B construction firm. She is also on the Audit Committee of ShoreTel (NASDAQ: SHOR), the Audit Committee of BayCare Health Systems, a $2B health care provider in central Florida and advises three West Coast technology growth companies. In a consulting role, Connie assisted PwC with the execution of its off-shoring strategy in India. In 2011, she joined the Board of the V Foundation for Cancer Research and is currently on the Executive and Finance Committees.
Connie served on the 18-member elected Board of U.S. Partners and Principals for PricewaterhouseCoopers, PwC, ($7B in revenues) for a four-year term prior to her formal retirement. Concurrently, Connie was the U.S.Tax Strategy Leader for the Firm. She was responsible for both short term and long term strategies for this $2B business. Earlier in her PwC career, she was West Region Tax Managing Partner where she was the equivalent of CEO for the $300M unit, managing the coordination of all tax compliance and consulting advice provided by the Firm for clients throughout the West.
Connie has over 30 years’ experience and has worked with a variety of public and privately held companies advising on accounting and tax strategies, global corporate structuring, due diligence projects, employee benefit plans, corporate mergers and acquisitions, stock options, and syndications. She served as the primary tax advisor on numerous initial public offerings and other SEC filings. During her years as an advisor, Connie developed deep expertise in the technology, manufacturing, and extractive industries. She rendered financial advice to over 300 clients including Hyundai Electronics, Micron Technology, Vulcan Capital (Charter Communications), Bechtel Group, Barrick Gold Corporation, Sega of America, and Plum Creek Timber.
Prior to joining PricewaterhouseCoopers, Connie was a tax specialist with the Internal Revenue Service. She holds a B.A. degree from Florida State University and a M.S. degree in Taxation from Golden Gate University. Recently, she completed the Directors College program at Stanford Law School.
Board of Directors
John Moriarty is an entrepreneur, real estate developer and investor. In the early 1990’s, John built and operated an amusement/thrill park in Biloxi, Mississippi. In 1997 he developed and owned the “Ultimate Rush Thrill Park” at the Reno Hilton Hotel & Casino in Reno, Nevada. In 2006, John was a partner and investor in the group that purchased the Reno Hilton Hotel and Casino from Caesar’s Entertainment at a price of $150 million and rebranded the hotel as the Grand Sierra Resort. In 2012, John sold his Ultimate Rush Thrill Park to the current owners of the Grand Sierra Resort.
John resides in Salt Lake City, Utah, where he developed and owns the two of the largest sushi bars in the state known as “Simply Sushi.” He has pioneered, through Simply Sushi, the endless sushi concept and is currently working on expanding into the wholesale sushi market supplying fresh sushi to over 40 supermarkets.
John first invested in Cyrcadia Health over three years ago. In the last year he became a major investor in the company. He has contributed countless hours and business expertise to assist in the fast tracking of the IT Bra to market. As a board member, John’s focus is to represent the numerous small investors who have helped finance the development of Cyrcadia Health’s innovative IT Bra. John received his BA in Economics and his MBA in Finance from the University of Wisconsin.
Reno, NV 89502